#### **ORIGINALLY FILED**

PTO/SB/8A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO

Sheet

Examiner

Initials

Cite

Nο

A2

**A3** 

A4

Number

3,042,587

4,065,355

4,233,405

5,279,823

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

U.S. Patent Document

Kind Code<sup>2</sup>

(if known)

	Complete if Known	D=0=0	L
Application Number	10/076,213	RECEIV	E
Filing Date	February 12, 2002		
First Named Inventor	CHAN, Hak-Kim	AUG 0 9 20	۱,2
Group Art Unit	1651	- AUG V J Z	UZ
Examiner Name			ì

FCH CENTER 1600/2900 Attorney Docket Number A-60010-1/RFT/DLR U.S. PATENT DOCUMENTS **Date of Publication** Pages, Columns, Lines, Where Relevant Name of Patentee or Applicant Cited Document Passages or Relevant MM-DD-YYYY of Cited Document Figures Appear 7/3/52 BAUMGARTEN et al 12/27/77 KHOUW, B.T., et al. 11/11/80 NEUBECK, C.E. 1/18/94 FRENZ et al.

				FOREIGN PATENT DOCUMEN	TS		
Examiner	Cite No.	Office	oreign Patent Document Kind Code <sup>2</sup> B <sup>3</sup> Number <sup>4</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°
754	B1	wo	90/07572	Shuk at d	7/12/90		
990	B2	wo	93/25670	Frem old,	12/23/93		
	<u> </u>						$\perp$
ļ			<u> </u>				igspace
	<u> </u>						1
		L					11
L		مـــا		<u> </u>	,		

Date Considered Examiner Signature

EXAMINER: Initial if reference considered. Whether or not citation is in conformance with MPEP 609. Draw lige through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type quus sign (+) inside this box [+]

#### COPY OF PAPERS **ORIGINALLY FILED**

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

A-60010-1/RFT/DLR

Under the Penerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB Under uncontrol number

Attorney Docket Number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 of Sheet

	Complete if Known	· LOE	JVED
Application Number	10/076,213		]
Filing Date	February 12, 2002	AUG 0 9	buus
First Named Inventor	CHAN, Hak-Kim		٢٥٥٧
Group Art Unit	1651	TECH CENTER	]
Evaminer Name		CENTER	1600/201

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ALI	C1	ARAKAWA, T., et al., "Stabilization of Protein Structure by Sugars," Biochemistry, 21:6436-6544 (1982).	
20	C2	BACK, J.F., et al., "Increased Thermal Stability of Proteins in the Presence of Sugars and Polyols," <i>Biochemistry</i> , 18(23):5191-5196 (1979)	
DI	СЗ	BELL, J.H., et al., "Dry Powder Aerosols I: A New Powder Inhalation Device," <i>Journal of Pharmaceutical Sciences</i> ," 60(10):1559-1564 (1971).	
A	C4	BROADHEAD, J., et al., "The Spray Drying of Pharmaceuticals," <i>Drug Development and Industrial Pharmacy</i> , 18(11 & 12):1169-1206 (1992).	
An	C5	CIPOLLA, D., et al., "Characterization of Aerosols of Human Recombinant Deoxyribonuclease I (rhDNase) Generated by Jet Nebulizers," <i>Pharmaceutical Research</i> , 11(4):491-498 (1994).	_
an	C6	CIPOLLA, D.C., et al., "Assessment of Aerosol Delivery Systems for Recombinant Human Deoxyribonuclease," S.T.P. Pharma Sciences, 4(1):50-62 (1994).	
920	C7	DOUVAS et al., "Some Effects of Calcium and Magnesium lons on the Activity of Bovine Pancreatic Deoxyribonnuclease A" (1975) Biochem. Biophys. Acta, 395(2), Pages 201-212.	
On On	C8	EICHHORN et al. (1969) J. Biol. Chem. 244(4), "The Interaction of Metal Ions with Polynucleotides and Related Compounds", pp. 937-942	_
	C9	FRANKS, F., et al., "Materials Science and the Production of Shelf-Stable Biologicals," BioPharm, pp. 38-42 & 55 (1991).	
Din	C10	GEKKO, K., "Calorimetric Study on Thermal Denaturation of Lysozyme in Polyol-Water Mixtures," J. Biochem, 91:1197-1204 (1982)	
Chi	C11	GRANDERTON, D., "The Generation of Respirable Clouds Form Coarse Powder Aggregates," Journal of Biopharmaceutical Sciences, 3(1/2):101-105 (1992	
Sol	C12	HUBBARD, R.C., et al., "A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis." The New England Journal of Medicine, 326(12):812-815 (1992).	L
SW	C13	KASSEM, N.M., et al., "The Effect of Air Flow and Carrier Size on the Characteristics of an Inspirable Cloud," Cheisea Department of Pharmacy, King's College, London SW3 6LX 14P in Auty, R., et al. Br. J. Dis. Ches., 81:371-380 (1987);	
9	C14	KASSEM, N.M., et al., "The Influence of Carrier Surface on the Characteristics of Inspirable Powder Aerosols, Character	
W)	C15	KIM, C.S., et al., "Particle Deposition in Bifurcating Airway Models with Varying Airway Geometry," J. Aerosol Sci., 25(3):567-581 (1994).	
h.	C16	LIAO, Ta-Hsiu, et al., "Bovine Pancreatic Deoxyribonuclease A, Isolation of Cyanogen Bromide Peptides; Complete Covalent Structure of the Polypeptide Chain," <i>The Journal of Biological Chemistry</i> , 248(4):1489-1495 (1973).	
711/11/	1 .		

V. 4		1 / 40			MA 11 -11
Examiner Signature	100	(A)		Date Considered (	08 Hm 09
Signature	/ 10 4	PENT	<del></del>		
	<del></del>	1 90 (	) .		on Death time through citation if not in

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Please type a bus sign (+) inside this box [

Sheet

Examiner

Signature

## COPY OF PAPERS ORIGINALLY FILED

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Patenwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known

**Attorney Docket Number** 

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

3 of 4

	Complete if Known	RECE	11 /
Application Number	10/176.213	HECE	IVEC
Filing Date	February 12, 2002	AUG	
First Named Inventor	CHAN, Hak-Kim	AUG 0 9	2002
Group Art Unit	1651		,
Examiner Name		TECH CENTED	

A-60010-1/RFT/DLR

TECH CENTER 600/29(

	/	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
PU	C17	LIZARRAGA et al., "Multiple Conformations of Deoxyribonucleic A, Their Separation at Alkaline pH and Low Ionic Strength in the Presence of Ca2+" (1979) Biochem. Biophys. Acta 579(2), Pages 298-302	
H	C18	LIZARRAGA et al., "The Role of Ca2+ on pH-Induced Hydrodynamic Changes of Bovine Pancreatic Deoxyribonnuclease A" (1978) J. Biol. Chem., 253(9), Pages 3191-3195.	
A	C19	LOURENCO, R.V., et al., "Clinical Aerosols, II. Therapeutic Aerosols," Arch. Intem. Med., 142:2299-2308 (1982).	
M	C20	LUNDBLAD, et al., "Purification and Partial Characterization of Deoxyribonuclease I from Bovine Parotid Gland," J. Dent. Res., 56(3):320-326 (1977).	
DH-	C21	MARKEY, F., "Rapid Purification of Deoxyribonuclease I Using Fast Protein Liquid Chromatography," Elsevier Science Publishes V.V., Federation of European Biochemical Societies, 167(1):155-159 (1989).	
OK	C22	MUMENTHALER, M., et al., "Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant Human Growth Hormone and Tissue-Type Plasminogen Activator," <i>Pharmaceutical Research</i> , 11(1):12-20 (1994).	
AX	C23	NEFSKY, B., et al., "Preparation of Immobilized Monomeric Actin and its Use in the Isolation of Protease-Free and Ribonuclease-free Pancreatic Deoxyribonuclease I," <i>Eur. J. Biochem.</i> , 179:215-219 (1989).	
M	C24	PRICE et al. (1969a) J. Biol. Chem., 244(4), "Properties of Chromatographically Purified Bovine Pancreatic Deoxyribonnuclease", pp. 917-923.	
H	C25	PRICE et al. (1196b)J. Biol. Chem., 244(4), "Alkylation of a HisPancreatidine Residue at the Active Site of Bovine Pancreatic Doexyribonuclease", pp 924-928.	
DU	C26	PRICE et al. (1196c)J. Biol. Chem., 244(4), * Effect of Devalent Cations on the Reduction and Re-Formation of the Disulfide Bonds of Deoxyribonuclease*, pp 929-932.	
TW	C27	PRICE, P.A., "The Essential Role of Ca2+ in the Activity of Bovine Pancreatic Deoxyribonnuclease" (1975) J. Biol Chem., 250(6) Pages 1981-1986	
W	C28	SCHELLMAN, J.A., Ann. Rev. Biophys. Chem. Rev., 16, "The Thermodynamic Stability of Proteins", Pages 115-137A	
M	C29	SCHMID, R.D., "Stabilised Soluble Enzymes," Advances in Biochemical Engineering, 12:42-118 (1979).	
W	C30	SHAK, S., et al., "Recombinant Human DNASE I Reduces the Viscosity of Cystic Fibrosis Sputum," Proc. Natl. Acad. Sci. USA, 98:9188-9192 (1990)	
11			

\*EXAMINER: Initial/if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

Considered

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

S 0 7 2002	(1)		[+]	ORIGINALLY FILED		PTO/SB/8B (08	-00)
der the Pa	700	sign (+) inside this box $\Box$ ork Reduction Act of 1995,		U.S. Patent and Trade are required to respond to a collection	mark Office: U.S. DEP	10/31/2002. OMB 0651-6 PARTMENT OF COMME it contains a valid OMB	0031 RCE
ntrol number	<b>**</b> /_	ite for form 1449B/PTO			Complete if Known		
TRADEMEN	Ostitu	ite for form 1449B/PTO		Application Number	10/076,213	DEOF	
IN	iFΩ	RMATION DISCL	OSURE	Filing Date	February 12, 2002	HEUL	-17
		EMENT BY APP		First Named Inventor	CHAN, Hak-Kim		$\neg \neg$
J	141	FIAIFIAI DI VLL		Group Art Unit	1651	AUG 0	9 7
	(us	se as many sheets as nec	essary)	Examiner Name			4
Sheet	4	of 4		Attorney Docket Number	A-60010-1/RFT/DL	R TEAL ATL	
3,1001	<u> </u>				_ <u> </u>	TECH CENTE	HI6
		OTHER	PRIOR AR	- NON PATENT LITERATURE	DOCUMENTS		
	Cite No.¹	Include name item (book, mag	azina inumal	(in CAPITAL LETTERS), title of the a l, serial, symposium, catalog, etc.), da publisher, city and/or country where pu	ite. pade(s). volume-is:	e), title of the sue number(s),	T²
m	C31	Sigma Chemie 'Sigma M		ogy' 1993 Product Catalog, Bornem: E			
De	C32	TULLIS et al., "The Effect Deoxyribonuclease A" (1	et of Calcium a 1974) J. Biol. (	and Magnesium on the Ultraviolet Spe Chem., 249(16), Pages 5033-5037	ectrum of Bovine Panc	reatic	
740	C33	VAN DEN BEEK, M.J., e and the Effect of Sugars	et al., "Presen and Certain (	vation of the Enzymatic Activity of Rer Other Additives," Neth. Milk Dairy J., 2	nnin During Spray Dryi 23:46-54 (1969).	ing and During Storage,	
	C34	VIDGREN, M., et al., "Ef of Pharmaceutics, 42:21	fect of Powde 1-216 (1988).	r Inhaler Design on Drug Deposition i	n the Respiratory Trac	t," International Journal	
77							
					<u> </u>		
	-						
							Щ

Examiner Signature Date Considered 02 Aproy

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.